Non-invasive decision support for NSCLC treatment using PET/CT radiomics
EGFR mutations are common in non-small cell lung cancer and patients with these mutations are treated with tyrosine kinase inhibitors. Here, the authors show that EGFR mutation status can be predicted from 18F-FDG-PET/CT images, which may enable the stratification of patients for treatment.
Main Authors: | Wei Mu, Lei Jiang, JianYuan Zhang, Yu Shi, Jhanelle E. Gray, Ilke Tunali, Chao Gao, Yingying Sun, Jie Tian, Xinming Zhao, Xilin Sun, Robert J. Gillies, Matthew B. Schabath |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2020-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-19116-x |
Similar Items
-
The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges
by: Qiuyuan Hu, et al.
Published: (2023-03-01) -
PET/CT Based EGFR Mutation Status Classification of NSCLC Using Deep Learning Features and Radiomics Features
by: Weicheng Huang, et al.
Published: (2022-04-01) -
PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology
by: M. Sollini, et al.
Published: (2017-03-01) -
Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics.
by: Janna E van Timmeren, et al.
Published: (2019-01-01) -
PET/CT Radiomics in Lung Cancer: An Overview
by: Francesco Bianconi, et al.
Published: (2020-03-01)